Alnylam Pharmace. buy StockNews.com
Start price
27.12.24
/
50%
€230.70
Target price
27.12.25
-
Performance (%)
48.29%
Price
19.12.25
€342.10
This prediction will end soon
Summary
This prediction is currently active. The BUY prediction by StockNews_com for Alnylam Pharmace. has seen massive gains of 48.29%. This prediction currently runs until 27.12.25. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 1.034% | 1.034% |
| iShares Core DAX® | 0.299% | 4.394% |
| iShares Nasdaq 100 | 0.666% | 1.175% |
| iShares Nikkei 225® | -0.656% | -0.055% |
| iShares S&P 500 | 0.352% | 1.378% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat